What is PD-L1, and why does it matter so much in your lung cancer treatment plan? Patient host Colette Smith talks with Dr. Julie Brahmer of Johns Hopkins University Hospital to demystify PD-L1 testing, immunotherapy decisions, and personalized lung cancer care.

You'll learn:

• What PD-L1 is and how cancer cells use it as a "cloaking device"
• How Tumor Proportion Scores (TPS) from 0 to 100 guide treatment choices
• When immunotherapy alone works—and when chemotherapy should be added
• Why repeat biopsies matter for long-term survivors
• The most common side effects of immunotherapy and how they're managed
• When immunotherapy may not be the right option
• Key questions to ask your oncologist at every stage of treatment
• Why every patient should ask about clinical trials

Whether you're newly diagnosed or navigating a treatment change, this conversation offers clarity, hope, and actionable guidance.

Get the full PD-L1 guide and download free patient resources: https://lcfamerica.org/about-lung-cancer/diagnosis/understand-pd-l1/

Heading to a doctor's appointment? Download LCFA's "Questions to Ask Your Care Team about PD-L1" PDF at lcfamerica.org.

Learn more at lcfamerica.org.

Guests:

• Dr. Julie Brahmer, Johns Hopkins University Hospital
• Colette Smith, Patient Host

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PD-L1-in-Lung-Cancer-Show-Notes.pdf Transcript - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PDL1-Transcript.pdf YouTube - https://youtu.be/Ymff6MwaJTc

Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.